KBC Lecture
\nTage-Erlander Professor 2011
\n\n
Paul Helquist
\nDepartment of Chemistry & Bi ochemistry\, University of Notre Dame\, Notre Dame\, Indiana
\n\n
Title:
\nFrom Simple Diene Chemistry to Therapies for R are and Neglected Diseases
\n\n
Abstract
\nIn a joint set of ventures\, the Wiest and Helquist laboratories at Notre Dam e\, specializing in computational chemistry and drug synthesis\, respectiv ely\, are supported by various funding mechanisms to reach out to investig ators in other fields and at many institutions to form multi-disciplinary collaborative teams for the purpose of drug development. Most often\, the external collaborators are at medical schools or other biomedical institut ions and have major strengths in biological or clinical studies but do not have the chemistry expertise required for drug development. These collabo rators have often identified a potential therapeutic protein target from c ellular studies\, or they have conducted compound screenings to identify i nitial hits. The next logical steps in these investigations are the design of protein binders or hit optimization\, requiring the computational and synthetic chemistry input of our laboratories. The resulting compounds are provided back to the external collaborators and other appropriate parties for more extensive biological studies. Over the past few years\, these co llaborative ties have been established with many investigators at Cornell University Weill College of Medicine\, Tufts University Medical School\, C olumbia University College of Physicians and Surgeons\, Washington Univers ity School of Medicine\, University of Texas Southwestern Medical Center\, Broad Institute\, Dana-Farber Cancer Institute\, Purdue University\, Stat e University of New York at Albany\, and Biological Sciences at Notre Dame .
\nThis presentation will place emphasis on the history of our deve lopment of synthetic methods for dienes\, especially with colleagues in Sw eden\, and the synthesis of target compounds as potential drugs for treati ng cancer and a rare\, inherited disease.
\n\n
Abstract with refer ences for download here
\nMore information about the Tage Erlander professor 2011
DTSTART;TZID=Europe/Stockholm:20111214T130000 DTEND;TZID=Europe/Stockholm:20111214T140000 SUMMARY:KBC Lecture - Paul Helquist: From Simple Diene Chemistry to Therapi es for Rare and Neglected Diseases URL:http://www.ucmr.umu.se/about-ucmr/events/162-ucmr-calendar/164-seminar/ 152-kbc-lecture-paul-helquist-from-simple-diene-chemistry-to-therapies-for -rare-and-neglected-diseases.html X-ALT-DESC;FMTTYPE=TEXT/HTML:KBC Lecture
\nTage-Erlander Professor 2011
\n\n
Paul Helquist
\nDepartment of Chemistry & Biochemistry\, University of Notre Dame\, Notre Dame\, Indi ana
\n\n
Title:
\nFrom Simple Diene Chemistry t o Therapies for Rare and Neglected Diseases
\n\n
Abs tract
\nIn a joint set of ventures\, the Wiest and Helquist laborato ries at Notre Dame\, specializing in computational chemistry and drug synt hesis\, respectively\, are supported by various funding mechanisms to reac h out to investigators in other fields and at many institutions to form mu lti-disciplinary collaborative teams for the purpose of drug development. Most often\, the external collaborators are at medical schools or other bi omedical institutions and have major strengths in biological or clinical s tudies but do not have the chemistry expertise required for drug developme nt. These collaborators have often identified a potential therapeutic prot ein target from cellular studies\, or they have conducted compound screeni ngs to identify initial hits. The next logical steps in these investigatio ns are the design of protein binders or hit optimization\, requiring the c omputational and synthetic chemistry input of our laboratories. The result ing compounds are provided back to the external collaborators and other ap propriate parties for more extensive biological studies. Over the past few years\, these collaborative ties have been established with many investig ators at Cornell University Weill College of Medicine\, Tufts University M edical School\, Columbia University College of Physicians and Surgeons\, W ashington University School of Medicine\, University of Texas Southwestern Medical Center\, Broad Institute\, Dana-Farber Cancer Institute\, Purdue University\, State University of New York at Albany\, and Biological Scien ces at Notre Dame.
\nThis presentation will place emphasis on the hi story of our development of synthetic methods for dienes\, especially with colleagues in Sweden\, and the synthesis of target compounds as potential drugs for treating cancer and a rare\, inherited disease.
\n\n
Ab stract with references for download here
\nMore information about the Tage Erlander profess or 2011
END:VEVENT BEGIN:VEVENT UID:d626659b30cd556ae3967fd534cd1feehttp://www.ucmr.umu.se DTSTAMP:20260521T025329Z CATEGORIES:General DESCRIPTION:\n
Department of Medical Biochemistry and Biophysi cs
\nDefence Licentiate Thesis
\n\n
Jenny Nordén
\n\n
Title:
\n\n
Multifaceted adhesion properties of H elicobacter pylori in promotion of gastric disease
\n\n
Su
pervisor: Thomas Borén
Place: Lilla hörsalen KB3A9\, KBC
\n
Department of Medical Biochemi stry and Biophysics
\nDefence Licentiate Thesis
\n\n
Jenny No rdén
\n\n
Title:
\n\n
Multifaceted adhesio n properties of Helicobacter pylori in promotion of gastric disease
\n< p style='margin: 0.0px 0.0px 0.0px 0.0px\; font: 12.0px Verdana\; min-heig ht: 15.0px\;'> \nSupervisor: Thomas Borén
Place: Lilla hörsalen K
B3A9\, KBC
Department of Clinical Microbiology
Extra Seminar
Title:
High-Throughput Screening in an Academic Setting\,
a Bona Fide Path to Novel Therapeutics and Tool Molecules?
Speaker:
Kurt Lackovic
Walter and Eli
za Hall Institute Melbourne\, Australia
Place: Betula\, Univ
ersity Hospital\, building 6 M
The Walter and E
liza Hall Institute of Medical Research was one of the first academic inst
itutions in the world to establish a high-throughput screening facility. H
ow this Facility operates\, along with the format of projects\, outcomes t
o date\, examples of projects\, and recent expansion to include high-conte
nt screening will be discussed.
\n
Biography Paragraph:
\nDr Kurt Lackovic completed his PhD in analytical chemistry in 2003. H e then relocated to Sweden for his initial post doctoral placement\, at th e Department of Medical Biosciences\, Umeå University\, Sweden. Dr Lackovi c returned to Melbourne in October 2006\, immediately taking a position in the WEHI High-Throughput Chemical Screening (HTCS) Facility. In his curre nt role\, Dr Lackovic is responsible for managing collaborative research p rojects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and reporting findings. In addition\, he is responsible for the HTCS Facility's high-content imag ing capabilities.
\n
Recent publications include:
Croker et al. Fas-mediated neutrophil apoptosis is accelerated
by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl AcadSci
U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP\, Sleebs N\, Bae
ll JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Street IP\, Kedziers
ki L. Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by
high-throughput screening of small-molecule chemical library. Antimicrob
Agents Chemother. 2010 54:1712-9.
Department of Clinical Microbiology
E
xtra Seminar
Title:
High-Throughput Screening in an Ac
ademic Setting\, a Bona Fide Path to Novel Therapeutics and Tool Molecules
?
Speaker:
Kurt Lackovic
Walter and Eliza Hall Institute Melbourne\, Australia
Pla
ce: Betula\, University Hospital\, building 6 M
The Walter and Eliza Hall Institute of Medical Research was one of the fi
rst academic institutions in the world to establish a high-throughput scre
ening facility. How this Facility operates\, along with the format of proj
ects\, outcomes to date\, examples of projects\, and recent expansion to i
nclude high-content screening will be discussed.
\n
Biograp hy Paragraph:
\nDr Kurt Lackovic completed his PhD in analytical che mistry in 2003. He then relocated to Sweden for his initial post doctoral placement\, at the Department of Medical Biosciences\, Umeå University\, S weden. Dr Lackovic returned to Melbourne in October 2006\, immediately tak ing a position in the WEHI High-Throughput Chemical Screening (HTCS) Facil ity. In his current role\, Dr Lackovic is responsible for managing collabo rative research projects seeking lead-like molecules across a broad range of target classes and disease types\, developing novel techniques\, and re porting findings. In addition\, he is responsible for the HTCS Facility's high-content imaging capabilities.
\n
Recent publicatio
ns include:
Croker et al. Fas-mediated neutrophil apoptosi
s is accelerated by Bid\, Bak\, and Bax and inhibited by Bcl-2 and Mcl-1.
Proc Natl AcadSci U S A. 2011 108:13135-40.
Lackovic K\, Parisot JP
\, Sleebs N\, Baell JB\, Debien L\, Watson KG\, Curtis JM\,Handman E\, Str
eet IP\, Kedzierski L. Inhibitors of Leishmania GDP-mannose pyrophosphoryl
ase identified by high-throughput screening of small-molecule chemical lib
rary. Antimicrob Agents Chemother. 2010 54:1712-9.